HIV RNA packaging and lentivirus-based vectors.

Area of Science:

• Molecular Biology
• Virology
• Gene Therapy

Background:

• Lentivirus vector research has surged since the mid-1990s due to their gene transfer capabilities.
• High-titer, helper-virus-free gene transfer to non-dividing cells is achievable with lentiviral vectors.
• Clinical trials using lentiviral vectors are anticipated in the near future.

Purpose of the Study:

• To review the advancements and current status of lentivirus-based vectors for gene therapy.
• To highlight the efficiency of HIV-1 based vectors and the importance of understanding viral assembly.
• To discuss the potential of non-HIV based vectors and the critical need for elucidating packaging mechanisms.

Main Methods:

• Review of existing literature on lentivirus vector development and applications.
• Analysis of viral packaging processes, including cis and trans packaging preferences.
• Evaluation of viral and cellular factors influencing lentiviral vector packaging efficiency.

Main Results:

• Human Immunodeficiency Virus type 1 (HIV-1) based vectors are currently the most efficient.
• Understanding of HIV-1 encapsidation and assembly processes is more advanced than for other lentiviruses.
• Non-HIV based vectors offer theoretical safety advantages but require further development.

Conclusions:

• Lentivirus vectors, especially HIV-1 derived, show great promise for gene therapy applications.
• Elucidating the packaging mechanisms in various lentiviruses is crucial for improving vector efficiency and safety.
• A deeper understanding of viral and cellular factors in the packaging pathway will drive future advancements.